Lirilumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lirilumab
Monoclonal antibody
Type Whole antibody
Source Human
Target KIR2DL1/2/3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6452H9918N1698O2030S46
Molar mass 145.2 kg/mol

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer.[1][2] It binds to KIR2DL1/2L3.[3]

This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.

Clinical trials[edit]

A phase 2 clinical trial for acute myeloid leukemia (AML)[4] was terminated early ("failed") in 2017.[5]

It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN),[6] but it may be abandoned.[7]

As of November 2017 nine clinical trials of lirilumab are registered as active.[8]

References[edit]